Publications:

Selected presentations by Senopsys staff include:

  • “Taste Masking of Super Bitter Actives”  INTERPHEX Annual Meeting, April 1, 2025.
    • Senopsys’ taste masking expert David Tisi was invited to speak on the latest tools, techniques, and approaches to mask the taste of the most bitter drug actives.
  • “Defining ‘Candy-Like’ Nonprescription Drug Products” Food And Drug Administration ONPD Public Meeting, October 30, 2023.
    • As OTC medications increasingly adopt formats like gummies and soft chews to improve adherence, the FDA is addressing the “regulatory gap” regarding safety risks and product definitions. Senopsys was invited to provide expert testimony at this pivotal workshop to help bridge the divide between patient appeal and pediatric safety. (Watch Here)
  • “Selecting Excipients for Improved Drug Palatability”  ExciPerience Conference. September 14, 2023.
    • The role of excipients on drug palatability is not often discussed.  Senopsys’ David Tisi spoke to the inherent challenges present in common drug excipients, and alternative choices that may improve the patient experience.
  • “Innovations and Advances in Drug Dosage Forms”  Drug Solutions Podcast. August 1, 2023.
    • In this episode, Senopsys’ David Tisi and Reenal Gandhi (Aptar Pharma) provide expert insights into advances and innovations changing the drug dosage form landscape.
  • “Taste Assessment and Optimization of Oral Formulations”  October 27, 2022 NJPhAST Meeting.
    • The development of palatable oral formulations is important to pediatric dosing compliance, bolstered by regulations in the United States and European Union. Senopsys’ Technical Director David Tisi provided an overview of sensory perception and strategies available to the formulator to develop palatable drug products.
  • “Taste Masking as an Alternative to Improve Patient Convenience and Compliance”  November, 2020 AAPS PharmSci 360 Annual Meeting.
    • Senopsys’ David Tisi spoke at the AAPS annual meeting, summarizing the aversive taste, aroma and mouthfeels of APIs studied by Senopsys and expanded on the 5 major technology approaches to taste masking.
  • “Sensory Evaluation of Norvir® (Ritonavir) 100 mg Powder for Special Populations” (AbbVie Inc. & Senopsys LLC.), November, 2019 AAPS PharmSci 360 Annual Meeting.
    • David Tisi and Jeff Worthington (Senopsys) with John B. Morris and David Cheng Thiam Tan (AbbVie) presented the results of a study to evaluate the flavor effects of an aqueous suspension of Norvir oral powder administered with seven different soft food vehicles.
  • “The Science of Taste Perception and Sensory Analysis”  (Symposia on Pediatric Drug Products), 2017 AAPS Annual Meeting – San Diego, CA.
    • Senopsys’ Jeff Worthington moderated a technical discussion on pediatric drugs with experts from industry and academia. The symposia covered the latest information on the science of taste and how quantitative methods of sensory analysis can inform appropriate drug taste masking strategies.
  • “Development Strategies for Age-Appropriate Pediatric Drug Products” David Tisi (Senopsys) 2017 Joint Meeting of the Southern California Pharmaceutical Discussion Group / Southern California American Chemical Society  (SCPDG/SDACS) 
  • “A Structured Taste Masking Process for Developing Palatable Pediatric Chewable Tablets”, David Tisi (Senopsys) 2017 Northeast Regional Discussion Group Annual Meeting
  • “Developing Palatable Drug Products: It’s More than Yuck and Yum”  David Tisi (Senopsys) 2017 AAPS Bay Area Discussion Group
  • “A Structured Taste Masking Process for Developing Palatable Pediatric Chewable Tablets” (Senopsys and Bristol-Myers Squibb), 2016 AAPS Annual Meeting.
  • “Flavor Profile Method of Descriptive Sensory Analys Development of a Solithromycin Pediatric Powder for Oral Suspension Formulation” (Senopsys, Cempra Inc., and Toyama Chemical Co., Ltd), 2015 AAPS Annual Meeting.
  • “Developing Palatable Pediatric Formulations” Pediatric Formulations Development Workshop, Jeff Worthington (Senopsys) ACCP Annual Meeting September 2013.
  • “Framework for Developing Palatable Paediatric Drug Products – The Tools and Approaches for Taste Masking” Jeff Worthington (Senopsys) Global Research in Paediatrics (GRiP) 4th “Meet the Expert” on Paediatric Formulations, June 2013.
  • “Development of Apixaban Oral Solution Formulation: Excipients and Palatability.” (Senopsys and Bristol-Myers Squibb), 2013 ASCPT Annual Meeting.
  • “Sensory-directed Taste Optimization of Pediatric Drug Products” (David Tisi, Guest Lecture), Concordia School of Pharmacy January 2013.
  • “Sensory-directed Taste Optimization of Pediatric Drug Products” (Short Course), Jeff Worthington (Senopsys) 2010 AAPS Annual Meeting.
  • “Taste Effects of Excipients Used in the Solubilization of Hydrophobic Drugs”, David Tisi (Senopsys) April, 2010 AAPS Northeast Regional Discussion Group.
  • “Pediatric Drug Delivery: Formulating Better Medicines for Children”, Jeff Worthington (Senopsys) and Dr. Susan Lum (Patheon Inc.), February, 2010 New Jersey Pharmaceutical Association for Science and Technology Meeting.
  • “An Investigation of the Relationship Between Eszopiclone Tablet Coating and Initial Dysgeusia Using the Flavor Profile Method” (Senopsys and Sepracor Inc.), 2009 AAPS Annual Meeting.
  • “Development of a Palatable, Oral Solution of Tolevamer™” (Senopsys and Genzyme), 2006 AAPS Annual Meeting.
  • “The Development of Palatable Pediatric Formulations – Establishing the Target, Measuring Progress and Verifying Acceptability,” Jeff Worthington (Senopsys) Pre-Clinical and Clinical Strategies for Pediatric Drug Development, February 2006.